We are developing amezosvatein (CRV-101), a non-mRNA, adjuvanted subunit vaccine for shingles (herpes zoster) and chickenpox (varicella). We’ve completed a successful Phase 2 trial in over 875 patients head-to-head versus Shingrix®, the most-used vaccine for shingles. The trial met its co-primary endpoints of efficacy and safety.

The Phase 2 trial results demonstrated amezosvatein has a non-inferior immune response with lower local and systemic adverse events compared to Shingrix.

If these results are confirmed in Phase 3 trials, we hope amezosvatein will increase the number of people effectively vaccinated for shingles by reducing vaccine hesitancy and second dose avoidance related to tolerability issues. We also hope to address current accessibility issues given amezosvatein has been developed for easy scale-up at different production sites to meet global demand.

The current chickenpox vaccines are wonderful examples of safe and effective vaccines making a big difference in reducing morbidity and mortality related to chickenpox. As live-attenuated virus (LAV) vaccines, however, they can be difficult to give to children and younger adults who have compromised immune systems. We are planning a Phase 1 trial of amezosvatein in immunocompromised children to address this unmet medical need.